Latest studies
- RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusCzechia - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusCzechia - RecruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
Small-cell Lung CancerCzechia - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightCzechia - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaCzechia - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaCzechia - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Czechia - AuthorisedTherapeutic confirmatory (Phase III)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
This study tests an inhaled dry powder medicine called treprostinil palmitil for adults with high blood pressure in the lungs linked to lung scarring. The trial lasts up to two years to see if the medicine is safe and helps improve breathing, walking ability, and overall quality of life.
Pulmonary Hypertension Associated with Interstitial Lung DiseaseCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Czechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
This phase 3 trial is testing a new targeted medicine called surovatamig (AZD0486) combined with rituximab for people newly diagnosed with follicular lymphoma. Researchers want to see if this new combination works better and is safer than standard chemotherapy combined with rituximab.
Follicular LymphomaCzechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
This study is testing a new tablet called CRD-4730 for adults with heart failure. Researchers want to see if the medicine can help the heart pump blood better, ease everyday symptoms, and improve quality of life. Participants will take either the study drug or a dummy pill for 24 weeks.
heart failureCzechia - AuthorisedTherapeutic exploratory (Phase II)
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
This study looks at a new drug combination for older or frail adults with diffuse large B-cell lymphoma, a type of blood cancer. Researchers want to see if adding an antibody drug called epcoritamab to standard, gentler chemotherapy helps clear the cancer better and keeps people well for longer.
Diffuse large B-cell lymphoma (DLBCL)Czechia - AuthorisedTherapeutic exploratory (Phase II)
A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
This clinical study tests an experimental gel called EscharEx for treating venous leg ulcers. Researchers want to find out if it safely removes dead tissue from the wound and speeds up healing compared to a dummy gel or usual non-surgical care. It is open to adults aged 18 and over.
Venous Leg Ulcer (VLU)Czechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
This study is testing a new tablet called ENV-294 for adults living with moderate-to-severe atopic dermatitis, also known as eczema. Researchers want to see if different doses of this medicine can calm inflamed skin, reduce itching, and remain safe and gentle for people to take.
Atopic DermatitisCzechia - AuthorisedTherapeutic confirmatory (Phase III)
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
Certain blood cancers can weaken your immune system, leaving you at higher risk of serious infections. This study tests whether an antibody drip called Gamunex-C, given alongside your usual medical care, can safely prevent severe bacterial infections and keep you out of hospital.
Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer
This study is testing a drug called trilaciclib for adults with limited-stage small cell lung cancer. Chemotherapy can damage bone marrow and lower white blood cells, raising infection risks. Researchers want to see if trilaciclib protects healthy blood cells and reduces side effects during standard cancer treatment.
Limited-stage small cell lung cancer (LS-SCLC)Czechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This clinical trial is testing a new targeted medicine called atebimetinib for advanced pancreatic cancer. Doctors want to see if adding this drug to standard chemotherapy helps people live longer and improves their quality of life compared to standard chemotherapy alone.
Metastatic Pancreatic Ductal AdenocarcinomaCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
This study is checking the long-term health of people who took part in an earlier trial for choroidal melanoma, a rare eye cancer. Researchers want to see how well a treatment called bel-sar protects vision and stops the tumour from growing or returning over several years.
Choroidal MelanomaCzechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
This clinical study tests an experimental tablet called soquelitinib for adults with moderate to severe atopic dermatitis, also known as eczema. Researchers want to see if the medicine is safe, easy to take, and able to reduce skin redness, dry patches, and itchy symptoms compared to a dummy tablet.
Atopic dermatitis (AD)Czechia - AuthorisedTherapeutic exploratory (Phase II)
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
This study tests a new daily tablet called AC01 for people with long-term heart failure. Researchers want to see if this medicine can help the heart pump blood more effectively. Participants take either the real medicine or a dummy tablet for 12 weeks while doctors monitor their heart health.
chronic advanced heart failure with reduced ejection fraction (HFrEF)Czechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
This clinical trial is testing a new combination vaccine designed to protect older adults against two common chest viruses: RSV and HMPV. Researchers want to find out how well the vaccine prevents lung infections, how safe it is, and whether it helps the immune system build strong protective defences.
Infections and infestationsCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
This Phase 3 clinical trial tests a new drug called mocertatug rezetecan for womb (endometrial) cancer. Researchers want to see if it works better and is safer than standard chemotherapy for people whose cancer has returned or worsened after earlier treatments like platinum chemotherapy and immunotherapy.
Neoplasms, EndometrialCzechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
This study tests a new medicine called ontunisertib for people with Crohn's disease who have narrowed sections in their bowel. Researchers want to find out if this daily capsule can reduce tough scar tissue, help widen the bowel, and improve symptoms compared to a dummy pill over one year.
Fibrostenosing Crohn’s DiseaseCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
This study tests a new medicine called claseprubart (DNTH103) for generalised myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if the medicine safely improves muscle strength and helps with daily activities compared to a dummy drug (placebo) in adults aged 18 and older.
generalized Myasthenia gravisCzechia - AuthorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
This 52-week clinical study is testing an experimental medicine called EXPD-101 for adults living with COPD. Researchers want to find out if taking this treatment can safely reduce chest flare-ups, ease breathing symptoms, and help people stay out of hospital compared with a dummy treatment (placebo).
Chronic Obstructive Pulmonary Disease (COPD) exacerbationsCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).
This clinical trial is testing a potential new medicine called pridopidine for adults with Huntington’s disease. Researchers want to see if taking this medicine daily for one year can safely help slow down changes in movement, thinking, and everyday tasks compared to an inactive dummy pill (a placebo).
Huntington’s disease (HD).Czechia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration
This study is testing an experimental capsule called STL303 for geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Researchers want to see if taking this medicine by mouth can protect light-sensing cells at the back of the eye and safely slow down vision loss over two years.
Geographic Atrophy Secondary to Age-related Macular DegenerationCzechia - AuthorisedTherapeutic confirmatory (Phase III)
J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
This study is testing a new medicine called eloralintide for adults who have type 2 diabetes, are overweight or obese, and have a higher risk of heart problems. Researchers want to see if taking this once-weekly injection helps people lose weight and safely lower their blood sugar levels.
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Overweight, ObesityCzechia - AuthorisedTherapeutic exploratory (Phase II)
A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD); the WINDWARD study
The WINDWARD study is testing a new medicine called mirivadelgat for adults with pulmonary hypertension caused by lung scarring (PH-ILD). Researchers want to see if taking this medicine for 12 weeks safely lowers blood pressure in the lungs, improves walking ability, and eases daily breathing symptoms compared to a dummy pill.
Pulmonary Hypertension associated with Interstitial Lung DiseaseCzechia - RecruitingTherapeutic confirmatory (Phase III)
A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants with Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid
This study is testing a medicine called elafibranor for adults with primary biliary cholangitis (PBC). It is for people whose regular treatment has not worked well enough or caused side effects. Researchers want to see if elafibranor can safely bring liver test results back to normal, healthy levels.
Primary Biliary Cholangitis (PBC)Czechia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)
This study tests a new injection called plozasiran in adults with high levels of blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fats over one year compared to a dummy jab (placebo). This could help reduce risks to the heart and pancreas.
HypertriglyceridemiaCzechia - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
This clinical trial is testing whether higher doses of a medicine called eteplirsen are safe and helpful for boys with Duchenne muscular dystrophy. It is for males with a specific genetic change that can be treated by skipping exon 51, aiming to protect muscle strength over nearly three years.
Duchenne Muscular DystrophyCzechia - RecruitingTherapeutic exploratory (Phase II)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
This study looks at an inhaled medicine called GB002 for adults with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs. Researchers want to see if taking this medicine over a longer time is safe and helps people walk further without getting out of breath.
Pulmonary Arterial Hypertension (PAH)Czechia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study is testing a new injection called ION-682884 for adults with a serious heart condition called ATTR-CM. Researchers want to find out if this medicine can protect the heart, lower the need for hospital care, and help people live longer compared to a dummy treatment (placebo).
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Czechia - RecruitingPHASE2
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
This study tests a new drug called bexmarilimab alongside a standard treatment (azacitidine) for adults newly diagnosed with higher-risk myelodysplastic syndromes (MDS). Researchers want to find the safest and most effective dose, and see if combining these treatments helps manage this blood condition better than standard treatment alone.
Higher Risk Myelodysplastic SyndromesCzechia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
This Phase 3 clinical study tests a new injection called plozasiran for adults with very high blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fat levels over 12 months compared to a dummy jab, reducing the risk of painful pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Czechia - RecruitingTherapeutic confirmatory (Phase III)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
This study looks at two medicines, rucaparib and nivolumab, for women with advanced ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if using these drugs after standard chemotherapy helps keep the cancer away for longer compared to dummy treatments, known as placebos.
Ovarian epithelialcancer, Malignant peritonealneoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopiantube, or primary peritoneal cancer (who responded to front-lineCzechia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
This study looks at whether adding immunotherapy drugs helps people with limited-stage small-cell lung cancer. Researchers want to see if giving durvalumab alone, or combined with tremelimumab, after chemoradiation keeps the cancer from returning and helps people live longer compared to a dummy treatment (placebo).
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)Czechia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
This study is testing a new tablet, called BLU-5937, for adults with a chronic cough that will not go away despite usual treatments. Researchers want to see if taking the tablet for 24 weeks safely reduces how often people cough during the day and night.
Refractory Chronic Cough, Including Unexplained Chronic CoughCzechia - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Czechia - RecruitingTherapeutic confirmatory (Phase III)
J5P-MC-GZRA: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA); J5P-MC-GZ01: Participants with OSA unable or unwilling to use PAP therapy; J5P-MC-GZ02: Participants with OSA on PAP therapy
This study is testing a once-daily tablet called orforglipron for adults living with overweight or obesity and obstructive sleep apnoea. Researchers want to see if the medicine helps improve night-time breathing over 52 weeks compared to a dummy pill (placebo).
Overweight or Obesity, OSA (Obstructive Sleep Apnea)Czechia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multinational, multicenter, randomized, double blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease.
This clinical study tests a new medicine called balinatunfib (SAR441566) for adults with moderate to severe Crohn's disease. Researchers want to see if different doses help heal the bowel lining and reduce symptoms compared to a dummy treatment (placebo), while checking for any unwanted side effects.
Crohn's diseaseCzechia - RecruitingTherapeutic exploratory (Phase II)
Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications
This study is testing an experimental tablet called CVN424 for Parkinson's disease. Researchers want to see if taking this medicine every day for 12 weeks reduces 'OFF time'—periods when usual Parkinson's medicines wear off and movement symptoms return—compared to a dummy pill.
Parkinson DiseaseCzechia - RecruitingHuman Pharmacology (Phase I)- Other
C5001001 - A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of PF-07868489 in Healthy Adult Participants And, Additionally, Clinical Activity of Repeat Doses in Participants With Pulmonary Arterial Hypertension
This study tests a new medicine called PF-07868489 for pulmonary arterial hypertension (high blood pressure in the lungs). Researchers are checking its safety in healthy volunteers, and finding out if repeated doses help improve blood flow and walking ability in adults living with the condition.
Pulmonary Arterial HypertensionCzechia - Active not recruitingPHASE3
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
This study is testing a medicine called viltolarsen for boys with Duchenne muscular dystrophy who can still walk. It is an extension study for children who already completed an earlier trial. Every participant receives the medicine through a weekly drip for nearly two years to check its safety and long-term effects.
Duchenne Muscular DystrophyCzechia - RecruitingTherapeutic exploratory (Phase II)
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Obese Individuals with Osteoarthritis of the Knee
This clinical trial is testing a new medicine called KBP-336 for adults living with obesity and knee osteoarthritis. Alongside a healthy diet and exercise, researchers want to see if KBP-336 helps reduce body weight and eases knee pain over six months, compared to an inactive dummy treatment (placebo).
Obesity, Knee osteoarthritisCzechia - RecruitingTherapeutic exploratory (Phase II)
C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
This clinical trial is looking at a new injection called PF-06835375 for adults with primary immune thrombocytopenia (ITP). ITP is a condition where the body attacks its own platelets, causing low platelet counts. The study tests whether the new medicine is safe and helps raise platelet levels.
Primary immune thrombocytopeniaCzechia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This clinical trial looks at whether giving two cancer medicines after liver cancer surgery or heat treatment helps stop the cancer returning. Researchers are comparing this combination of medicines against standard regular hospital check-ups in adults who have a higher chance of their liver cancer coming back.
High-risk hepatocellular carcinoma (HCC)Czechia - RecruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
This study tests a new tablet version of mesalazine for people with mild to moderate ulcerative colitis. Researchers want to see if it is just as safe and effective as an established treatment at calming gut inflammation and helping symptoms settle down after eight weeks of daily treatment.
Ulcerative colitisCzechia - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)
This phase 3 clinical study tests a new medicine called sparsentan for adults with IgA nephropathy, a serious kidney condition. Researchers want to see if sparsentan is better at reducing protein leaks in urine and protecting kidney function over time compared to a standard medicine called irbesartan.
Immunoglobulin A Nephropathy (IgAN)Czechia